Business Context and Reporting Period
This Form 8-K filing by Catalyst Biosciences, Inc. (CBIO) reports on events occurring on February 12 and February 13, 2020. The company is a biopharmaceutical firm focused on developing treatments for autoimmune diseases, specifically mentioning clinical activities for MarzAA and DalcA.
Key Financial Metrics
- Capital Raise: Entered into an underwriting agreement to sell 4,615,385 shares of common stock at $6.50 per share.
- Net Proceeds: Estimated at approximately $27.8 million, excluding the exercise of an underwriters' option for up to 692,307 additional shares.
- Liquidity Position: Preliminary, unaudited cash, cash equivalents, and short-term investments were approximately $76.9 million as of December 31, 2019.
- Recent Inflow: The December 31, 2019 liquidity figure excludes a $15 million upfront payment received from Biogen International GmbH in January 2020.
- Revenue/Profit: The filing text does not provide specific revenue, profit, or margin figures for the period.
Material Changes
The primary material change is the execution of a public offering to raise capital. The company expects the offering to close on February 18, 2020. This transaction significantly alters the company's capital structure and cash position compared to the prior period, pending the closing of the deal.
Outlook, Management Commentary, and Risks
- Use of Proceeds: Net proceeds will be used for general corporate purposes, including clinical and manufacturing activities for MarzAA and DalcA, R&D, capital expenditures, SG&A costs, facilities expansion, and working capital.
- Financial Statement Status: The liquidity figures provided are preliminary and unaudited. The company expects to complete audited financial statements for the year ended December 31, 2019, subsequent to the offering.
- Risks/Contingencies: The preliminary cash balance is subject to change and potential material adjustments upon the completion of the audit. The offering is subject to customary closing conditions.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds of the offering once the transaction completes.
- Review the audited financial statements for the year ended December 31, 2019, to confirm the final cash balance and any adjustments to the preliminary $76.9 million figure.
- Confirm the total cash position including the $15 million Biogen payment received in January 2020.
- Monitor the exercise of the 30-day underwriters' option for additional shares.